Teniposide
From Wikipedia, the free encyclopedia
Teniposide
|
|
Systematic (IUPAC) name | |
? | |
Identifiers | |
CAS number | 29767-20-2 |
ATC code | L01CB02 |
PubChem | 34698 |
DrugBank | APRD00649 |
Chemical data | |
Formula | C32H32O13S |
Mol. weight | 656.655 g/mol |
Pharmacokinetic data | |
Bioavailability | n/a |
Protein binding | >99% |
Metabolism | Hepatic (CYP2C19-mediated) |
Half life | 5 hours |
Excretion | Renal and fecal |
Therapeutic considerations | |
Pregnancy cat. | |
Legal status |
℞-only(US) |
Routes | Intravenous |
Teniposide (Vumon®, VM-26) is a chemotherapeutic medication mainly used in the treatment of childhood acute lymphocytic leukemia. It is in a class of drugs known as podophyllotoxin derivatives and slows the growth of cancer cells in the body. Common side effects include nausea, vomiting, diarrhea, and thinned or brittle hair.
The medication is injected though a vein and burns if it leaks under the skin. It is sometimes used in combination with other anticancer drugs.
A major problem with teniposide is the lowered count of white blood cells 1-2 weeks after treatment. Though they should return to normal after 3-4 weeks, the decreased count puts a user at a risk of infection. The same also occurs for platelets.